Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, specifically targeting the NBD1 region to treat cystic fibrosis (CF) patients
Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, specifically targeting the NBD1 region to treat cystic fibrosis (CF) patients.
Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, specifically targeting the NBD1 region to treat cystic fibrosis (CF) patients
Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, specifically targeting the NBD1 region to treat cystic fibrosis (CF) patients.